The Supreme Court's April 2026 argument in Monsanto Company v. Durnell places a familiar doctrine—federal preemption—in an unusually consequential posture. At issue is a narrow but high-stakes question: whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts a state-law failure-to-warn claim where the Environmental Protection Agency (EPA) has not required the warning at issue. The implications are anything but narrow. The Court's answer will determine not only the viability of thousands of pending pesticide cases, but also the practical boundary between federal regulatory approval and state tort law.
The Core Dispute: What Does “Uniformity” Actually Require?
Monsanto's position, reflected in its merits briefing and at argument, is straightforward. The company argues that FIFRA creates a uniform, federally controlled labeling regime. Under this framework, a manufacturer cannot unilaterally add warnings without EPA approval. Therefore, Monsanto contends that a state-law rule requiring additional warnings creates an impossibility conflict. In other words, Monsanto frames the case as one about regulatory exclusivity: once the EPA has approved a label—and declined to require a cancer warning—state tort law cannot impose liability for failing to include one. That argument is reinforced by significant amicus support, including the federal government, emphasizing the risk of a “patchwork” of state labeling obligations.
The respondent, John L. Durnell, advances a narrower conception of preemption. Durnell argues that state law does not impose labeling requirements in the abstract; rather, it imposes liability for failure to warn based on known risks. According to this view, FIFRA permits parallel state-law duties that do not directly contradict federal requirements. Critically, Durnell argues that federal law sets a floor, not a ceiling, and that nothing in FIFRA prohibits manufacturers from seeking label changes or otherwise addressing emerging risks.
The Briefing: Competing Views of Impossibility
The briefing crystallizes the dispute into two competing theories of “impossibility.”
Monsanto’s Impossibility Theory
Monsanto argues that compliance with both regimes is impossible because FIFRA prohibits unilateral label changes and the EPA did not require a cancer warning. Therefore, any state-law duty to include such a warning is preempted. This is not merely a labeling argument—it is an argument about regulatory finality. Once the EPA has acted (or declined to act), that determination governs.
Durnell’s Parallel-Duties Framework
Durnell responds that FIFRA allows manufacturers to propose label changes, and state law requires only reasonable warnings based on known risks. There is no direct conflict because federal law does not forbid the conduct state law requires. Under this view, impossibility requires more than regulatory silence—it requires an affirmative federal prohibition, which is absent here.
Oral Argument: Where the Case Will Likely Turn
The oral argument on April 27, 2026, suggests that the Court is less interested in abstract preemption doctrine than in how the regulatory system actually functions in practice. Several themes emerged during the proceedings.
What Happens Between EPA Reviews?
Multiple justices pressed Monsanto on a practical problem: if new scientific evidence emerges between EPA reviews, what is the manufacturer supposed to do? Monsanto's position—that labeling must await EPA action—raises the possibility of a regulatory gap. That concern appeared to resonate, particularly where the underlying tort claim is based on failure to warn of evolving risks.
Is EPA Silence Equivalent to Prohibition?
A central question at argument was whether the EPA's failure to require a warning should be treated as a binding federal determination (Monsanto's view) or a non-exclusive regulatory judgment that leaves room for state law (Durnell's view). This distinction is outcome-determinative. If silence equals prohibition, preemption follows. If it does not, the case proceeds.
Retroactive Liability and Fairness
Some justices focused on fairness concerns, questioning whether it is appropriate to impose liability for failing to include a warning that the EPA did not require, and whether that effectively punishes compliance with federal law. These questions reflect a recurring tension in preemption cases: whether state tort law complements or undermines federal regulation.
The Scope of the Court’s Prior Precedents
Although not framed explicitly as a stare decisis case, the argument repeatedly returned to earlier decisions recognizing that state failure-to-warn claims can coexist with federal labeling regimes. Durnell's position depends on those precedents remaining intact. Monsanto's position would, in practical effect, narrow them significantly.
The Structural Stakes: More Than Glyphosate
Although the case arises from claims involving glyphosate-based herbicides, the doctrinal stakes extend well beyond any single product. At a structural level, the Court is deciding whether federal regulatory approval displaces state tort law by default, or whether state law remains a parallel mechanism for risk regulation and compensation.
A ruling for Monsanto would likely curtail not only pesticide litigation, but also other areas where federal labeling regimes intersect with state tort claims. Conversely, a ruling for Durnell would preserve the existing equilibrium—one in which federal agencies set baseline requirements and state law fills perceived gaps.
Likely Paths Forward
Based on the briefing and argument, three outcomes appear plausible:
| Potential Outcome | Court’s Holding | Practical Effect |
|---|---|---|
| Broad Preemption (Monsanto Prevails) | EPA approval (or non-requirement) of a warning preempts state-law claims. | Significant reduction in failure-to-warn litigation across industries. |
| Narrow Preemption (Fact-Specific Holding) | Adopts a more limited rule tied to the specific regulatory record. | Continued litigation, with case-by-case preemption analysis. |
| No Preemption (Durnell Prevails) | FIFRA does not preempt parallel state-law failure-to-warn claims. | Preservation of existing litigation frameworks. |
Conclusion
Monsanto v. Durnell is framed as a technical preemption case. It is not. At bottom, the case asks whether federal regulatory approval is dispositive—or merely one input in a broader system of risk regulation that includes state tort law. The Court's answer will define not only the scope of FIFRA, but also the practical relationship between federal agencies and the common law.
For litigants, the takeaway is straightforward: the outcome will shape how—and whether—failure-to-warn claims proceed in any industry where federal regulation and state law operate in parallel. At Tajima LLP, we will continue to monitor the Court's decision and its implications for product liability and regulatory compliance litigation.